secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001104659-24-115287
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium posts record Q3 revenue $159.3M, up 17%; names Vikram Karnani CEO
---------------------------------------------------------------------------

- Q3 net revenue $159.3M (record), up 17% YoY; GAAP net income $9.3M ($0.27 diluted EPS).
- Adjusted EBITDA $105.1M, up 18% YoY; non-GAAP adjusted EPS $1.61.
- Reaffirms FY2024 guidance: product revenue $620-635M, adjusted EBITDA $395-405M.
- Appoints Vikram Karnani as President and CEO effective Nov 12, 2024; Heffernan remains Chairman.
- Closed Ironshore acquisition (Jornay PM) in Sep 2024, entering ADHD neurology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000110465924115287/0001104659-24-115287-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000110465924115287/tm2427748d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-115287

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer